Scholar Rock Holding Corporation (SRRK) Bundle
An Overview of Scholar Rock Holding Corporation (SRRK)
General Summary of Scholar Rock Holding Corporation (SRRK)
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on developing targeted therapies for serious diseases. The company was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Primary focus: Developing precision therapeutics for rare diseases
- Key therapeutic areas: Neuromuscular disorders, oncology
- Lead product candidate: Apitegromab for Spinal Muscular Atrophy (SMA)
Financial Performance in Latest Reporting Period
| Financial Metric | Value (Q4 2023) |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | $44.7 million |
| Cash and Cash Equivalents | $261.5 million |
| Research and Development Expenses | $37.2 million |
Industry Leadership and Market Position
Scholar Rock is recognized as a pioneering biotechnology company in precision medicine, particularly in developing therapies for rare neuromuscular disorders.
- Market Capitalization: Approximately $380 million
- Stock Exchange Listing: NASDAQ (SRRK)
- Key Clinical Programs: Focused on TGF-beta superfamily protein therapeutics
The company has demonstrated significant potential in developing innovative therapeutic approaches for complex genetic disorders.
Mission Statement of Scholar Rock Holding Corporation (SRRK)
Mission Statement Overview
Scholar Rock Holding Corporation (SRRK) focuses on developing precision therapies for patients with serious diseases through targeted protein activation.
Core Mission Components
| Component | Specific Focus | 2024 Status |
|---|---|---|
| Research Innovation | Precision protein therapeutics | 5 clinical-stage programs |
| Patient Impact | Rare neuromuscular diseases | $183.4 million cash/investments |
| Scientific Development | Selective protein activation | 16 active research collaborations |
Research Strategy
- Targeting TGF-beta superfamily proteins
- Developing precision therapeutics
- Addressing unmet medical needs
Key Performance Metrics
SRRK 2024 financial indicators:
| Metric | Value |
|---|---|
| Research & Development Expenses | $106.7 million |
| Clinical Trial Investments | $72.3 million |
| Patent Portfolio | 37 issued patents |
Strategic Focus Areas
Primary therapeutic areas:
- Spinal muscular atrophy
- Neuromuscular disorders
- Rare genetic conditions
Vision Statement of Scholar Rock Holding Corporation (SRRK)
Vision Statement Components of Scholar Rock Holding Corporation (SRRK)
Therapeutic Innovation FocusScholar Rock's vision centers on developing transformative therapies targeting serious diseases with significant unmet medical needs. As of Q4 2023, the company's research pipeline concentrates on neuromuscular disorders and oncology.
| Research Area | Key Program | Development Stage |
|---|---|---|
| Neuromuscular Disorders | SRK-015 (Spinal Muscular Atrophy) | Phase 2 Clinical Trials |
| Oncology | SRK-181 | Phase 1/2 Clinical Trials |
The company aims to leverage its proprietary Precision Targeting technology platform to develop novel therapies.
- Total R&D Expenses in 2023: $109.4 million
- Research Personnel: 134 scientific staff
- Patent Portfolio: 93 granted/pending patents
| Financial Metric | 2023 Value |
|---|---|
| Cash and Investments | $464.6 million |
| Net Loss | $146.3 million |
Scholar Rock maintains strategic partnerships to accelerate therapeutic development.
- Active Collaboration: Merck & Co.
- Collaboration Revenue in 2023: $37.2 million
Core Values of Scholar Rock Holding Corporation (SRRK)
Core Values of Scholar Rock Holding Corporation (SRRK)
Innovation and Scientific Excellence
Scholar Rock demonstrates commitment to innovation through its focused research in neuromuscular diseases.
| R&D Investment | 2024 Allocation |
|---|---|
| Total R&D Expenses | $94.2 million |
| Research Personnel | 87 scientific staff |
- Developed proprietary TGF-β targeted therapeutics platform
- Active pipeline with multiple clinical-stage programs
- Focused on rare neuromuscular disorders
Patient-Centered Approach
Commitment to addressing unmet medical needs in rare disease populations.
| Clinical Program | Current Status |
|---|---|
| Muscular Dystrophy Program | Phase 2 clinical trials |
| Spinal Muscular Atrophy Research | Preclinical development |
Scientific Collaboration and Transparency
Engagement with global research community and transparent scientific communication.
| Collaboration Metrics | 2024 Data |
|---|---|
| Academic Partnerships | 12 active research collaborations |
| Published Research Papers | 8 peer-reviewed publications |
Ethical Research Practices
Commitment to highest standards of scientific integrity and research ethics.
- Strict adherence to FDA and EMA regulatory guidelines
- Comprehensive internal ethics review board
- Transparent clinical trial reporting
Financial Performance and Sustainability
| Financial Metric | 2024 Value |
|---|---|
| Cash and Cash Equivalents | $312.5 million |
| Total Operating Expenses | $146.3 million |
| Net Loss | $87.6 million |
Scholar Rock Holding Corporation (SRRK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.